Business Context and Reporting Period
This Form 8-K Current Report was filed by Perrigo Company Limited on October 21, 2013. The registrant is incorporated in Ireland with principal executive offices in Dublin. The filing primarily addresses corporate governance changes and provides disclosures regarding ongoing merger transactions.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
- Compensatory Arrangement: Intertrust Management Ireland Limited will provide corporate administrative services for an initial fee of EUR 5,000.
- Director Compensation: The newly appointed director, Lorraine Egan, will receive no compensation for her services.
Material Changes
The primary material change reported is the appointment of Lorraine Egan as a director of the Company on October 21, 2013. Ms. Egan is an employee of Intertrust Management Ireland Limited and will serve on the Company's Audit Committee. Her appointment is pursuant to a Corporate Services Agreement dated October 22, 2013.
Outlook, Risks, and Contingencies
The filing highlights significant contingencies related to the "Transactions" (merger) between Elan Corporation plc, Perrigo Company Limited, and their respective subsidiaries. Ms. Egan's service as a director is expected to terminate upon the consummation of these transactions.
Risks and Forward-Looking Statements: The Company notes that actual results may differ from expectations due to:
- Successful completion of the Transactions and realization of anticipated synergies.
- Timing or outcome of regulatory agency approvals.
- Risks and uncertainties normally incident to the pharmaceutical industry.
Investor Verification Checklist
- Verify the status and expected closing date of the merger transactions with Elan Corporation plc.
- Confirm the terms of the Corporate Services Agreement with Intertrust Management Ireland Limited.
- Review the Company's Registration Statement on Form S-4 for detailed risk factors regarding the Transactions.
- Monitor regulatory approval timelines for the proposed merger.